Toradol (Ketorolac) is Contraindicated in the Third Trimester of Pregnancy
Ketorolac must be avoided at approximately 30 weeks gestation and later in pregnancy due to the risk of premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios. This is a strong contraindication based on FDA labeling and multiple clinical guidelines 1, 2, 3, 2, 4.
Why Ketorolac is Dangerous in Late Pregnancy
The FDA drug label explicitly states that ketorolac can cause premature closure of the fetal ductus arteriosus when used at about 30 weeks gestation or later 4. Additionally, NSAID use at about 20 weeks gestation or later has been associated with fetal renal dysfunction leading to oligohydramnios and in some cases neonatal renal impairment 4.
The 2020 American College of Rheumatology guideline provides the clearest directive: "We strongly recommend against use of NSAIDs in the third trimester because of the risk of premature closure of the ductus arteriosus" 1, 2. This recommendation is echoed by the 2025 EULAR guidelines 3 and multiple other authoritative sources.
Specific Timing Considerations
- After 28-30 weeks: NSAIDs including ketorolac should be completely avoided 5, 3
- Between 20-28 weeks: If absolutely necessary, use only the lowest effective dose for the shortest duration (maximum 7-10 days), with close monitoring 3
- Before 20 weeks: Short-term use may be considered if clinically necessary, though data on safety are limited 6
Fetal Risks in the Third Trimester
When ketorolac is used in late pregnancy, documented risks include:
- Premature closure or constriction of the ductus arteriosus
- Pulmonary hypertension in the newborn
- Oligohydramnios (reduced amniotic fluid)
- Impaired fetal renal function and reduced urine output
- Increased risk of intracranial and cutaneous bleeding in the fetus 7, 4
The 2023 ESMO consensus on breast cancer during pregnancy specifically notes that NSAIDs "should be avoided, particularly after 28 weeks of gestation because they may cause premature closure of the fetal ductus arteriosus and oligohydramnios as they reduce fetal renal function mainly if administered for >48 h" 5.
Safe Alternatives for Pain Management
For pain control in the third trimester, consider:
- Paracetamol (acetaminophen): The analgesic of choice for mild to moderate pain during any stage of pregnancy 5
- Short-term opioids: Safe when needed for adequate pain control 5
- Regional analgesia techniques: Safe and effective during pregnancy 5
Critical Clinical Caveat
If ketorolac was inadvertently used between 20-30 weeks for more than 48 hours, ultrasound monitoring for oligohydramnios is recommended 4. If oligohydramnios is detected, discontinue the medication immediately and follow up according to clinical practice 4.
The evidence is unequivocal: ketorolac and other NSAIDs pose significant fetal risks in the third trimester and should be strictly avoided after 28-30 weeks gestation to prevent serious cardiovascular and renal complications in the fetus.